Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp.
Your view on PHIOW
Overview
What the company does, where it operates, and who runs it.
About Phio Pharmaceuticals Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gerrit Dispersyn Med. Sc
- Headquarters
- 257 Simarano Drive, Marlborough, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gerrit Dispersyn Med. Sc
- Headquarters
- 257 Simarano Drive, Marlborough, MA, US
Established in 2011 and headquartered in Marlborough, Massachusetts, Phio Pharmaceuticals Corp. is a biotechnology firm dedicated to advancing immuno-oncology treatments within the United States. Central to its approach is the proprietary INTASYL therapeutic platform, engineered to counteract the mechanisms by which tumors evade or suppress the body's natural immune response. Its pipeline features several promising candidates: PH-762 is designed to inhibit the PD-1 checkpoint protein found on immune cells, with development focused on applications in adoptive cell transfer (ACT). PH-804 targets TIGIT, another suppressive immune receptor and checkpoint protein present on both T cells and natural killer cells, also intended for ACT. PH-790 focuses on modulating the PD-L1 protein, which typically prevents immune cells from attacking healthy tissues. Phio Pharmaceuticals actively collaborates with leading institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München. Furthermore, it maintains a strategic partnership with AgonOx Inc. specifically for the clinical advancement of innovative T cell-based immunotherapies for cancer. The company underwent a name change in November 2018, transitioning from its former identity as RXi Pharmaceuticals Corporation.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Phio Pharmaceuticals Corp., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Phio Pharmaceuticals Corp.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Phio Pharmaceuticals Corp.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Phio Pharmaceuticals Corp.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Phio Pharmaceuticals Corp.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Phio Pharmaceuticals Corp. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Phio Pharmaceuticals Corp., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Phio Pharmaceuticals Corp. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Phio Pharmaceuticals Corp.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Phio Pharmaceuticals Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Phio Pharmaceuticals Corp.. Press releases and market coverage, newest first.